Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / SCGB2A1



This biomarker is also known as:
  • Lipophilin-C,
  • mammaglobin-2,
  • mammaglobin 2,
  • O75556,
  • MGC71973,
  • secretoglobin, family 2A, member 1,
  • Lacryglobin,
  • lacryglobin,
  • mammaglobin B,
  • Secretoglobin family 2A member 1,
  • lipophilin-C,
  • lipophilin C,
  • LPHC,
  • UGB3,
  • mammaglobin-B,
  • LIPHC,
  • MGB2,
  • Mammaglobin-2,

View in BioMuta


SCGB2A1, also known as MGB2 or mammaglobin B, encodes a small secreted protein from the secretoglobin family, part of the uterglobin superfamily. SCGB2A1 is normally expressed in the thymus, trachea, kidney, steroid responsive tissues (prostate, testis, uterus, breast and ovary) and salivary gland.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


SCGB2A1, also known as MGB2 or mammaglobin B, is highly homologous to mammaglobin A (MGB1), which is overexpressed in breast cancer. SCGB2A1 has also been found to be overexpressed in primary breast cancers. Recently SCGB2A1 was found to be a top differentially expressed gene in ovarian cancer.

Performance Comment

SCGB2A1 was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. SCGB2A1 was not in the group of 13 selected for further validation.



Phase: One
QA State: Under Review


Performance Comment


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.